-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Eiger BioPharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to 2023.
- Eiger BioPharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2023 was -$13.5M, a 46.5% increase year-over-year.
- Eiger BioPharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2023 was -$75M, a 22.5% increase year-over-year.
- Eiger BioPharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$75M, a 22.5% increase from 2022.
- Eiger BioPharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$96.8M, a 185% decline from 2021.
- Eiger BioPharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$33.9M, a 47.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)